Exploration of neuroprotective therapy最新文献_第6页

Advancing Diagnosis and Treatment of Niemann-Pick C disease through Biomarker Discovery. 通过发现生物标志物推进Niemann-Pick C病的诊断和治疗。

Exploration of neuroprotective therapy Pub Date : 2021-12-30 DOI: 10.37349/ent.2021.00012

Xuntian Jiang, Daniel S Ory

{"title":"Advancing Diagnosis and Treatment of Niemann-Pick C disease through Biomarker Discovery.","authors":"Xuntian Jiang, Daniel S Ory","doi":"10.37349/ent.2021.00012","DOIUrl":"https://doi.org/10.37349/ent.2021.00012","url":null,"abstract":"Niemann-Pick C is a rare neurodegenerative, lysosomal storage disease caused by accumulation of unesterified cholesterol. Diagnosis of the disease is often delayed due to its rarity, the heterogeneous presentation and the early non-specific symptoms. The discovery of disease-specific biomarkers - cholestane-3β,5α,6β-triol (C-triol), trihydroxycholanic acid glycinate (TCG) and N-palmitoyl-O-phosphocholineserine (PPCS, initially referred to as lysoSM-509) - has led to development of non-invasive, blood-based diagnostics. Dissemination of these rapid, sensitive, and specific clinical assays has accelerated diagnosis. Moreover, the superior receiver operating characteristic of the TCG bile acid biomarker and its detection in dried blood spots has also facilitated development of a newborn screen for NPC, which is currently being piloted in New York state. The C-triol, TCG and PPCS biomarkers have also proven useful for monitoring treatment response in peripheral tissues, but are uninformative with respect to treatment efficacy in the central nervous system (CNS). A major gap for the field is the lack of a validated, non-invasive biomarker to monitor the course of disease and CNS response to therapy.","PeriodicalId":73000,"journal":{"name":"Exploration of neuroprotective therapy","volume":"1 3","pages":"146-158"},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963791/pdf/nihms-1765288.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9847487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Peroxisomes in intracellular cholesterol transport: from basic physiology to brain pathology 细胞内胆固醇转运中的过氧化物酶体:从基本生理学到脑病理学

Exploration of neuroprotective therapy Pub Date : 2021-12-06 DOI: 10.37349/ent.2021.00011

Jian Xiao, B. Song, Jie Luo

引用次数: 1

Maternal imprinting, mitochondrial DNA, nuclear DNA and Alzheimer’s disease 母体印记，线粒体DNA，核DNA和阿尔茨海默病

Exploration of neuroprotective therapy Pub Date : 2021-10-29 DOI: 10.37349/ent.2021.00010

Alberto Pérez-Mediavilla, Marta Zamarbide

引用次数: 1

Immunization with neural-derived peptides as a neuroprotective therapy for spinal cord injury 神经源性肽免疫作为脊髓损伤的神经保护疗法

Exploration of neuroprotective therapy Pub Date : 2021-10-12 DOI: 10.37349/ent.2021.00009

A. P. Ibarra-García, A. Ibarra

引用次数: 0

T-cell based immunotherapies for Parkinson’s disease 基于T细胞的帕金森病免疫疗法

Exploration of neuroprotective therapy Pub Date : 2021-10-03 DOI: 10.37349/ent.2021.00007

R. Pacheco

{"title":"T-cell based immunotherapies for Parkinson’s disease","authors":"R. Pacheco","doi":"10.37349/ent.2021.00007","DOIUrl":"https://doi.org/10.37349/ent.2021.00007","url":null,"abstract":"Current evidence indicates that neurodegeneration of dopaminergic neurons of the substantia nigra associated to Parkinson’s disease is a consequence of a neuroinflammatory process in which microglial cells play a central role. The initial activation of microglial cells is triggered by pathogenic protein inclusions, which are mainly composed by α-synuclein. Importantly, these pathogenic forms of α-synuclein subsequently induce a T-cell-mediated autoimmune response to dopaminergic neurons. Depending on their functional phenotype, these autoreactive T-cells might shape the functional features of activated microglia. T-cells bearing pro-inflammatory phenotypes such as T-helper (Th)1 or Th17 promote a chronic inflammatory behaviour on microglia, whilst anti-inflammatory T-cells, such as regulatory T-cells (Treg) favour the acquisition of neuroprotective features by microglia. Thus, T-cells play a fundamental role in the development of neuroinflammation and neurodegeneration involved in Parkinson’s disease. This review summarizes the evidence indicating that not only CD4+ T-cells, but also CD8+ T-cells play an important role in the physiopathology of Parkinson’s disease. Next, this review analyses the different T-cell epitopes derived from the pathogenic forms of α-synuclein involved in the autoimmune response associated to Parkinson’s disease in animal models and humans. It also summarizes the requirement of specific alleles of major histocompatibility complexes (MHC) class I and class II necessaries for the presentation of CD8+ and CD4+ T-cell epitopes from the pathogenic forms of α-synuclein in both humans and animal models. Finally, this work summarizes and discusses a number of experimental immunotherapies that aim to strengthen the Treg response or to dampen the inflammatory T-cell response as a therapeutic approach in animal models of Parkinson’s disease.","PeriodicalId":73000,"journal":{"name":"Exploration of neuroprotective therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41402895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry 大麻素受体2在神经精神病学中的治疗潜力

Exploration of neuroprotective therapy Pub Date : 2021-08-02 DOI: 10.37349/ent.2021.00006

M. García-Gutiérrez, F. Navarrete, A. Gasparyan, J. Manzanares

引用次数: 4

Neurological complications during HIV infection HIV感染期间的神经并发症

Exploration of neuroprotective therapy Pub Date : 2021-06-29 DOI: 10.37349/ent.2021.00004

J. Martinez-Navio

引用次数: 2

Cholesterol in autism spectrum disorders 自闭症谱系障碍中的胆固醇

Exploration of neuroprotective therapy Pub Date : 2021-06-20 DOI: 10.37349/ent.2021.00003

R. Franco, Rafael Rivas-Santisteban, Gemma Navarro, Irene Reyes-Resina

{"title":"Cholesterol in autism spectrum disorders","authors":"R. Franco, Rafael Rivas-Santisteban, Gemma Navarro, Irene Reyes-Resina","doi":"10.37349/ent.2021.00003","DOIUrl":"https://doi.org/10.37349/ent.2021.00003","url":null,"abstract":"The autism spectrum disorder (ASD) comprises a series of neurological diseases that share serious alterations of the development of the central nervous system. The degree of disability may vary so that Asperger’s may have a relatively normal life and get positions of responsibility in corporations and even in Governments, whereas other ASD sufferers are fully dependent on caregivers and have serious cognitive deficits. Although the first cases of autism were detected by looking at failures in metabolism, e.g., phenylketonuria, to later identify the faulty gene, today the trend is the opposite, first obtaining the exome and minimizing the look for altered parameters in blood, urine, etc. Cholesterol is key for neural development as it is not able to cross the blood brain barrier. Therefore, any gene or environmental factor that affects cholesterol synthesis will impact early developmental stages eventually leading to a disease within the autism spectrum and/or schizophrenia. This review provides data of the relevance of cholesterol dyshomeostasis in autism spectrum disorders. Determining biochemical parameters in body fluids should help to provide new therapeutic approaches in some cases of autism.","PeriodicalId":73000,"journal":{"name":"Exploration of neuroprotective therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49165034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

P2X7 receptor involvement in COVID-19 disease P2X7受体参与COVID-19疾病

Exploration of neuroprotective therapy Pub Date : 2021-04-19 DOI: 10.37349/ENT.2021.00002

P. Illés

引用次数: 1

Science plus technology to address challenges in determining the efficacy of neuroprotective/neurorestorative therapies 科学加技术解决在确定神经保护/神经修复疗法的疗效方面的挑战

Exploration of neuroprotective therapy Pub Date : 2021-01-24 DOI: 10.37349/ENT.2021.00001

R. Franco

引用次数: 1